大馬教育部副部長張盛聞訪台促台馬人才交流

大馬教育部副部長張盛聞訪台促台馬人才交流

   馬來西亞教育部副部長張盛聞及馬來西亞商業及工業協會理事長劉康捷一行11人於8日拜會僑務委員會，由委員長吳新興接見。吳新興表示，希望透過台馬人才交流，建立緊密合作的鏈結，共創互惠互利的「新南向政策」。

   吳新興提到，馬來西亞來台就學的華生逾1萬6千人，透過人才流動強化台馬兩地對彼此的了解，進一步帶動雙邊經貿、教育、觀光等各領域的合作。他表示，僑委會扮演海內外華人的聯絡平台，結合政府各部會及地方縣市政府的力量，配合新南向政策，將台灣的經驗與東南亞地區國家分享和交流，達到互榮互利。

   張盛聞表示，馬國政府近年大力推廣技職教育，僑委會會擴大辦理海青班及3+4加值型招生方案，培育出許多專業技術人才，將優良技術基礎帶回馬來西亞，在當地就業或創業，均有優異表現。

張盛聞表示，台灣物價合宜、生活品質良好，讓許多來台就學的大馬學子都希望畢業後留台發展。他特別提到台灣的醫療、教育、人力資源開發、技術創新、農業、防災等各種軟實力對東南亞地區深具影響力，希望透過訪台交流，更深入的認識台灣。

   劉康捷感謝僑委會對馬來西亞留台同學的協助，未來將持續建立台馬橋梁，希望和僑委會共同促進台馬友好互動關係，推動雙邊與多邊交流合作。

新英格蘭北大校友今(5/7)日迎校長助母校辦招聘

轉載

北京大学新英格兰校友会2017年年会暨北大人才招聘宣讲会5月7日@Harvard

2017-05-01 PKUAANE

各位北大校友和校际友人们，

漫漫寒冬已远去，明媚暖阳报春来。为庆祝北京大学119岁生日暨北大新英格兰校友会成立23周年，北京大学新英格兰校友会将于5月7日在哈佛大学召开年会。我们在此向广大北大校友以及所有关心北大的朋友们发出最诚挚的邀请，欢迎各界人士共同参与庆祝 。

此次年会特别荣幸邀请到了北京大学林建华校长及北大人才招聘代表团，林建华校长将带领大家一起了解北大的过去与现在，并共同展望无限可能的未来，也借着欢庆的时刻将北大的橄榄枝伸向有志于回国发展的各领域人才。

在这里，您将听到林校长对北大未来发展的规划蓝图，也有机会与代表团成员进行面对面交流，探讨国内学术岗位的机遇和挑战 。同时您也可以结识更多志同道合的朋友及校友，了解北大新英格兰校友会的日常活动，并在新的一年里跟校友会一起度过更丰富的业余生活。此次活动也提供免费晚餐。

科学民主的校园精神深深地影响着我们几代人，湖光塔影涤荡在每一个北大人的心中。从北大到波士顿，从美丽的校园到遥远的美东， 忆往昔携手奋斗，记今朝共聚波城，畅未来你我北大人，“这竟是夙缘”。北大新英格兰校友会真诚地期待您的到来！

时间：2017年5月7日，2点-5点
地点：Emerson Hall 210, Harvard University (Department of Philosophy), 25 Quincy Street, Cambridge, MA 02138

注册：免费，请点击“阅读原文”进行注册

年会主题： 守正创新，引领未来。

年会议程：

与林建华校长面对面机会难得，不容错过，数量有限，先到先得！

Governor Baker, Local Officials Celebrate Opening of Dorchester’s Finnegan Park

Governor Baker, Local Officials Celebrate Opening of Dorchester’s Finnegan Park

15 Acre Former Industrial Site Converted to Open Recreational Space for Massachusetts Families

BOSTON – Governor Charlie Baker today announced the opening of Senator Joseph Finnegan Park at Port Norfolk on the banks of the Neponset River, which will provide the families and residents of Dorchester with a 15-acre recreational site built upon the remains of a longtime industrial property. The governor was joined by Energy and Environmental Affairs (EEA) Secretary Matthew Beaton, Boston Mayor Marty Walsh, Department of Conservation and Recreation (DCR) Commissioner Leo Roy and elected city and state officials, who were on hand to celebrate the hard work by neighborhood advocates over the past 30 years to re-purpose state property into a close-to-home state park.

“We are proud to have converted this waterfront property along the Neponset River into open space for Dorchester’s residents to enjoy,” said Governor Baker. “A fitting tribute to Senator Finnegan and his family’s service, this park will honor his legacy and provide local families a recreational space in which they can grow and thrive.”

“I’m grateful to the many people who worked to make the Neponset River Greenway, and now this park, a reality,” said Mayor Martin J. Walsh. “I'd like to thank all the elected officials, neighbors and supporters who created a Neponset River waterfront that everyone can take pride in and enjoy.”

In 2014, the DCR identified $4.25 million in capital funding to acquire, clean and rehabilitate the location that would eventually become Finnegan Park. Located in lower Neponset and adjacent to Pope John Paul II Park, the site formerly housed two lumber companies that loaded wooded products onto the Old Colony Railroad for distribution and for construction of many structures around Dorchester. As a result of prior land uses, the space became contaminated by uncontrolled releases of hazardous wastes. The neighborhood, consisting of well-organized and concerned citizens, eliminated its industrial usage following a takeover by the state in 1986. After remediation and debris removal, the site sat fallow for decades until recently.

“The opening of Senator Joseph Finnegan Park at North Point is the result of the commitment of many to ensure access to open space in an urban setting,” said Energy and Environmental Affairs Secretary Matthew Beaton. “By providing the residents of Dorchester with a newly refurbished park, we are continuing our commitment to environmental protection while honoring the legacy of Senator Finnegan.”

“The Department of Conservation and Recreation is pleased to add this urban parkland to our collection of nearly half a million acres of protected spaces across the Commonwealth,” said DCR Commissioner Leo Roy. “Natural settings like Finnegan Park are important to the health and vitality of urban families and residents, and we look forward to bringing this park the attention, and attendance, that befit its name.”

“Senator Joseph Finnegan Park is a new beginning for the Port Norfolk community of Dorchester that came to fruition after the hard work and tireless activism by the Port Norfolk Neighborhood Association and dedicated residents in the area,” said Senator Linda Dorcena Forry (D-Dorchester). “I was proud to work with my colleagues Representative Dan Hunt and City Councilor Frank Baker, as well as Patrick and Baker Administrations to ensure that this community’s vision became a reality. This collaborative effort transformed a formerly polluted eye sore into the jewel of our neighborhood that families can enjoy for generations to come.”

“The entire Dorchester Community is so proud of this new vista of the mouth of the Neponset River,” said State Representative Dan Hunt (D-Boston). “This new $4 million dollar project has been years in the making and we appreciate the work of the administration. We will continue to work with the neighborhood and other stakeholders for progress on what is truly one of the jewels of the city.”

“The opening of Senator Joseph Finnegan Park is a welcome addition to the Port Norfolk neighborhood and the surrounding communities, and is a tremendous step forward in the completion of the Neponset River Greenway,” said Boston City Councilor Frank Baker.

With connections to surrounding parkland, Finnegan Park will be a key continuation of the reservation’s Neponset River Trail for cyclists and walkers, and features expansive green spaces with trees and rolling hills. Its name was established by legislation in 1987 to honor the memory of State Senator Joseph Finnegan, who represented Dorchester during the Great Depression.

CAPAC Members Mark 135th Anniversary of the Chinese Exclusion Act

CAPAC Members Mark 135th Anniversary of the Chinese Exclusion Act

WASHINGTON, D.C. – May 6, 2017 marks the 135th anniversary of the enactment of the Chinese Exclusion Act of 1882, which was the first law to expressly target and prohibit a specific group from immigrating to the United States. The law was signed by President Chester A. Arthur and imposed a ten-year ban on Chinese immigration or naturalization. It was reauthorized and expanded several times in the following decades, and was not repealed until 1943. In 2012, Congress passed a bipartisan resolution introduced by CAPAC Chair Rep. Judy Chu (CA-27), which formally expressed regret for the passage of the Chinese Exclusion Act. To commemorate the 135th anniversary of the Chinese Exclusion Act, CAPAC Members released the following statements:

Congresswoman Judy Chu (CA-27), CAPAC Chair:

“The Chinese Exclusion Act was one of the most discriminatory laws ever passed in our nation’s history, and it left permanent scars on the Chinese American community. It split families apart, created a second-class citizenry, and disenfranchised an entire ethnic community. In fact, my own grandfather who had been here legally since 1904 was forced to carry a certificate of registration at all times for almost 40 years, or risk deportation.

“Unfortunately, 135 years after the Chinese Exclusion Act was signed into law, our nation is once again debating whether an entire group of people should be banned from entering the United States based on their country of origin. This is unacceptable. Now more than ever, we must ensure that policies targeting immigrants, Muslims, and refugees, like President Trump’s un-American Muslim ban, do not succeed. The Chinese Exclusion Act was one of the darkest periods in our nation’s history, and we cannot allow history to repeat itself.”

Congresswoman Grace Meng (NY-06):

“The Chinese Exclusion Act, enacted 135 years ago today, was a dark mark in our in our nation’s history. Steeped in prejudice and bigotry, it was the first law to prevent a specific ethnic group from entering the United States, despite the fact that Chinese laborers made vital contributions to the United States, such as by helping to build the Transcontinental Railroad. Only in 1943 was this law repealed. On the 135th anniversary of this terrible law, may we reflect on our true identity as a nation of immigrants, a nation that does not discriminate based on race, national origin, or religion, a nation that promotes opportunity for all.”

美中生物醫藥協會今日 5/6 慶10週年

轉載

CABA美中生物医药协会2017年会暨十周年庆典召开在即

Original 2017-04-27 Jo Lee CABA

“Boston BioForum 2017”

CABA10th Annual Conference

May 6, 2017

🏨Boston Marriott Newton

📍2345 Commonwealth Ave, Newton, MA 02466

🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.

SPEAKERS

Gordon Freeman

Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School.  Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cellactivation (B7-2/CD28).

Carmen Bozic, MD

Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.

Kenneth I Kaitin, Ph.D.

Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.

Ken LeClair, Ph.D.

Ken LeClair received his undergraduate degree from Bowdoin College and a Ph.D. in Immunobiology from Yale University.

He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.

He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.

Samarth Kulkarni, Ph.D.

Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 

Xinyu Weng, Ph.D.

Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point of contact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.

Hui Cai, Ph.D.

Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate Communications.

Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases.

Lynn Yang, MBA

Lynn Yang is focusing on healthcare investment. Prior to joining Sequoia Capital in May, 2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare.  

Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Yongzhong Wang, Ph.D.

Dr. Yongzhong Wang is the President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group. He manages API manufacturing, sales and international regulatory affairs of the group, as well as Simcere Europe.  Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China. 

James (Jianguo) Yang, Ph.D.

Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.

Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.

Agenda

09:00 - 10:00 am       Registration / Social Networking

10:00 - 10:05 am       Opening Remarks, Kevin Fang, Ph.D., Conference Chair, President-Elect, CABA

10:05 - 10:15 am       Introduction of CABA, Eric Shi, Ph.D., President, CABA

Session I – Novel Therapies for Cancer and Neurological Diseases

SESSION CHAIR:        Lan Cao, Ph.D. and Cindy Yang, MBA.

10:15 - 10:50 am      Samarth Kulkarni, Ph.D., Chief Business Officer, CRISPR Therapeutics.

“CRISPR-based Therapeutics: Making it a Reality in Asian Markets”

10:50 - 11:25 am       Ken LéClair, VP, Technical Development and Manufacturing, Editas Medicine.

“Development of Cell and Gene-Edited Products”

11:25 - 12:00 pm       Carmen Bozic, M.D., SVP Global Develop, Biogen.

“Innovationsin Intrathecal Antisense Oligonucleotide Therapy for Neurological Diseases”

LUNCH AND VENDOR SHOW: 12:00 - 1:30 pm (LunchProvided on Site)

LUNCHEON PRESENTATION

12:45 - 1:05 pm         John Yao, Ph.D., Co-founder and CEO, TC Scientific Inc.

“A CRO’s View of the Pharma Landscape” hosted by Ellen Fan, MSc

SESSION II – Global Innovation, Investment,and Entrepreneurship

SESSION CHAIR: Jian Shao, MBA

1:30 - 2:05 pm    Hui Cai, Ph.D., VP of Corporate Alliances and Head of Communications, WuXi AppTec.

“Platformand Ecosystem for R&D Transformation”

2:05 - 2:40 pm    James Yang, Ph.D., President and CEO, Abpro-China.

“Strategic Partnership for Success in Biologics"

2:40 - 3:15 pm    Yongzhong Wang, Ph.D., President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group.

“Innovationsacross the Border, a Personal Journey”

3:15 - 3:50 pm    Lynn Yang, MBA, General Manger, Sequoia Capital “Sequoia China Healthcare Investment Strategy”

3:50 - 4:20 pm    COFFEE BREAK AND VENDOR SHOW

SESSION III - Global Pharma Trends, CFDA Regulatory Reform and Scientific Advancement in PD-1 Research

SESSION CHAIRS: Wendy Yang, MBA and Susan Qu,Ph.D., MBA

4:20 - 4:55 pm    Kenneth Kaitin, Ph.D., Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

“The Global Landscape for Pharmaceutical R&D: Current Trends - Future Opportunities”

4:55 - 5:30 pm    XinYu Weng, Ph.D., MBA, First Secretary of the Embassy of the China to the USA.

“Overview of CFDA Drug Regulatory Reform”

5:30 - 6:05 pm    Gordon Freeman, Dana-Farber Cancer Institute, Professor, Medicine, Harvard Medical School.

"PD-1Cancer Immunotherapy"

6:05 - 6:10 pm    Closing Remarks

6:10 - 8:30 pm    10th Anniversary Evening Celebration

Key Feature: Former Presidents’ Documentary Film

6:50 - 7:50 pm    Dinner

7:50 - 8:30 pm    Performances

Registration

Link: http://caba-annualmeeting-2017.eventdove.com（请复制此链接并在浏览器中打开）

也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association